Medikal Teknik September 2020

44
of Intensive Care, Istanbul Faculty of Medicine Hospital,
who started a scientific study based on the results of the
blood product, which is commonly called IVIG and used in
the treatment of immune deficiencies and various other
autoimmune diseases, in COVID-19 treatment pioneered
the conduct of further clinical trials around the world.
Following these positive data from the Istanbul University,
Istanbul Faculty of Medicine Hospital, Phase 3 studies were
initiated to assess the effectiveness and safety of IVIG in
COVID-19 patients in different centers in the USA.
Prof. Dr. Figen Esen reported in a statement on the
subject: “Treatment of sepsis, known as multiple organ
failure, involves antimicrobial therapy, focal control,
hemodynamics, respiratory support, and the modulation
of the immune system in addition to other organ support
systems. Human IVIG treatment in sepsis showed positive
effects on the inflammatory response, and it was noted
that these results increased survival rates. In order for
our studies to take their rightful place in treatment
guidelines, clinical trials with a large sample size are
needed. Theoretically, human IVIG treatment seems to
be an excellent option for modulating a patient’s immune
system. Although there are certain limitations regarding
our results, in intensive care patients with severe COVID-19,
the treatment in question could lead to a decrease in
CRP levels as an inflammatory marker at an early stage,
which leads to a better clinical outcome. We are pleased
to see that the results of our data are paving the way for
prospective, randomized, multi-center studies conducted
with severe COVID-19 patients requiring intensive care
treatment. Currently, as a team, we are looking forward to
the results.”
bir seçenek gibi durmaktadır. Sonuçlarımızın bazı belirli
sınırlamaları olmasına rağmen, şiddetli COVID-19’lu
hastalarda yoğun bakımda, erken dönemde söz konusu
tedavinin inflamatuar belirteç olarak CRP düzeylerinde
azalmaya neden olarak daha iyi bir klinik sonuca yol açtığını
gözlemlemiş bulunuyoruz. Verilerimizin sonuçlarının,
yoğun bakım tedavisine ihtiyaç gösteren şiddetli COVID-
19’lu hastalar ile prospektif, randomize, çok merkezli
çalışmaların önünü açtığını görmekten memnuniyet
duymaktayız. Şu anda ekip olarak büyük bir heyecanla
sonuçları beklemekteyiz.”
Eylül - September 2020